Trial · NCT01029782

Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis

NCT01029782, Phase 2, Completed, Kelowna General Hospital; results first posted 2018-08-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis. Trials, record NCT01029782. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01029782

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis
NCT number: NCT01029782
Status: Completed
Phases: Phase 2
Enrollment: 206 participants, actual
Lead sponsor: Kelowna General Hospital
Conditions: Cellulitis
Interventions: IV cefazolin plus oral probenecid and placebo cephalexin, Oral cephalexin and saline IV plus probenecid placebo
First posted: 2009-12-10
Last updated: 2018-08-13
Results first posted: 2018-08-13

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.	72 hours

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.	72 hours	Per-Protocol Analysis at 72 hours.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin		6		Participants
The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.	Oral Cephalexin and Saline IV Plus Probenecid Placebo		4		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	102
Overall Study	STARTED	Oral Cephalexin and Saline IV Plus Probenecid Placebo	104
Overall Study	COMPLETED	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	99
Overall Study	COMPLETED	Oral Cephalexin and Saline IV Plus Probenecid Placebo	96
Overall Study	NOT COMPLETED	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	3
Overall Study	NOT COMPLETED	Oral Cephalexin and Saline IV Plus Probenecid Placebo	8

Source ClinicalTrials.gov

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrhoea	Gastrointestinal disorders	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	0	102	0
other	Diarrhoea	Gastrointestinal disorders	Oral Cephalexin and Saline IV Plus Probenecid Placebo	2	101	2
other	Nausea	Gastrointestinal disorders	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	0	102	0
other	Nausea	Gastrointestinal disorders	Oral Cephalexin and Saline IV Plus Probenecid Placebo	1	101	1
other	Vomit	Gastrointestinal disorders	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	3	102	3
other	Vomit	Gastrointestinal disorders	Oral Cephalexin and Saline IV Plus Probenecid Placebo	1	101	1
other	Infusion Reaction	Vascular disorders	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	1	102	1
other	Infusion Reaction	Vascular disorders	Oral Cephalexin and Saline IV Plus Probenecid Placebo	0	101	0
other	Rash	Skin and subcutaneous tissue disorders	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	0	102	0
other	Rash	Skin and subcutaneous tissue disorders	Oral Cephalexin and Saline IV Plus Probenecid Placebo	1	101	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	0	102
Total, all-cause mortality	Oral Cephalexin and Saline IV Plus Probenecid Placebo	0	101
Total, other adverse events	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	4	102
Total, other adverse events	Oral Cephalexin and Saline IV Plus Probenecid Placebo	5	101
Total, serious adverse events	IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin	0	102
Total, serious adverse events	Oral Cephalexin and Saline IV Plus Probenecid Placebo	0	101

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
29914924	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin vs Oral Cephalexin and Saline IV Plus Probenecid Placebo: The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.	Trial comparisons
IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin vs Oral Cephalexin and Saline IV Plus Probenecid Placebo: deaths from any cause	Trial comparisons
IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin vs Oral Cephalexin and Saline IV Plus Probenecid Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01029782

GET https://conductscience.org/api/trials/v1/NCT01029782/registered

API reference For AI assistants